Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Activists in St. Louis want Washington University—with its multibillion-dollar endowment—to pony up to help rebuild public ...

We argue against selling Geron at current prices, citing strong market potential of imetelstat and Royalty Pharma deal ...

On the precipice of a winless road trip, the Kings limped into Raleigh for Saturday’s finale of a five-game trek, in which they’ll be opposed by the Carolina Hurricanes. For the ’Canes, the ...

With drivetrains so anemic, we're shocked none of them shriveled up like raisins, plus styling like an NPC vehicle in a video game; the Fairmont was just about rock bottom for the Ford brand.

The Duke of Sussex has settled his High Court claim against the publisher of The Sun, News Group Newspapers (NGN) over allegations of unlawful information-gathering. The settlement marks the end ...